Accelerating Efficacious & Safer Bispecific, Trispecific & Multispecifics
The bispecific and multispecific antibody field is advancing rapidly, fuelled by strong clinical readouts, growing biopharma investment, and increasingly sophisticated antibody designs. As programs evolve beyond first-generation bispecifics toward trispecific and multispecific strategies, the industry is sharpening its focus on improving efficacy while expanding the therapeutic window through improved safety and toxicity profiles.
With an increasing number of bispecifics progressing toward the clinic, the inaugural World Bispecific Summit Europe brings Europe’s bispecific leaders together for the first time, building on the proven success of the World Bispecific Summit US.
This industry-led forum delivers deep technical discussions and case studies spanning novel antibody formats, next-generation TCEs, and bispecific ADCs, accelerating bispecifics from bench to clinic through conditional activation strategies, co-stimulation, and translational insights.
With clinical momentum accelerating and unresolved challenges still to solve, now is the time to connect, collaborate, and shape the future of bispecific therapies. Join a high-calibre community in London, July 2026, and be part of the next wave of precision-driven care.
I see strong value in participating in this meeting because it allows for meaningful scientific and strategic exchange with leaders across the field. Engaging with peers outside UCB helps widen perspectives, challenge assumptions, and identify opportunities for collaboration or innovation.
Shirley Peters, Director of Antibody Engineering, UCB
As the industry is straying away from mono-specific antibodies. A major challenge is producing “developable” molecules with the correct function, geometry and potency. Finding out what others are doing in this space at World Bispecific Summit Europe is essential to drive programs forward.
Matthew Lambert, Senior Director, Pfizer
I look forward to engaging with other experts in the field to share perspectives on advancing bispecific antibody development and optimizing the benefit–risk balance.
Kristel Kemper, Director, Team Lead Early Translational Medicine & Research, Genmab
Explore the Full Event Guide
- Hear from 25+ world-class speakers across pharma and biotech sharing cutting-edge data on bispecific antibodies, T-cell engagers, and next-generation multispecific formats advancing toward clinical success
- Connect with 60+ senior attendees driving innovation in solid tumour targeting, immune cell redirection, and next-generation engineering strategies
- Gain insights from 20+ data-driven presentations covering translational challenges, safety optimisation, potency enhancement and strategies to improve clinical durability
- Take part in a dedicated Scientific Poster Session, spotlighting novel targets, platform technologies, and preclinical-to-clinical translation data
- Unlock 7+ hours of high-value networking, designed to foster strategic collaborations, partnerships, and pipeline acceleration
Official Partners
Expertise Partners
Exhibition Partners
Attending Companies Include
Explore Related Events
![CB-CDx-0690-min-scaled11[1]](https://bispecific-europe.com/wp-content/uploads/sites/317/2024/06/CB-CDx-0690-min-scaled111.jpg "CB-CDx-0690-min-scaled11[1]")
Explore the Agenda
Hear the latest industry breakthroughs and gain exclusive insights during our packed agenda, interactive roundtables, and panel discussions.
![CB-CDx-0330-min-scaled11[1]](https://bispecific-europe.com/wp-content/uploads/sites/317/2024/06/CB-CDx-0330-min-scaled111.jpg "CB-CDx-0330-min-scaled11[1]")
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
![Join-Biopharma-Experts11[1]](https://bispecific-europe.com/wp-content/uploads/sites/317/2024/06/Join-Biopharma-Experts111.png "Join-Biopharma-Experts11[1]")
Join Biopharma Experts
Be part of the hottest conversations with like-minded attendees spanning all stages of drug development and make critical connections during our dedicated networking sessions.